EnGeneIC Limited   Report issue

For profit Phase 1
Founded: Sydney Australia (2000)
Status: Left NME R&D (2014)

Organization Overview

First Clinical Trial
2014
NCT02369198
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

EnGeneIC Pty Limited

Active Ingredients

Drugs in Phase 1 Trials (3)

egfr(v)-edv-dox (1 trial)

mitoxantrone (novantrone) (1 trial)

targomirs (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Central Nervous System Neoplasms (Phase 1)

Glioblastoma (Phase 1)

Lung Neoplasms (Phase 1)

Mesothelioma (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3